ADMETRx is building new and improved ADME tools. The technology, a mix of wet lab analysis and computer modeling, attempts to move beyond the go/no go decisions typical of ADME.Instead the company offers clients a ranking of a drugs being tested based on the individual properties being tested.

Summarizing the month in European dealmaking.

Summarizing the month in European dealmaking.

Biotechs raising series C and D rounds, even those which have made their technology or commercial milestones, are finding that VCs aren't willing to give them a step-up in valuation from their previous round of financing. For management, the situation means more dilution, but VCs, even those who paid up in previous rounds, like the new prices, in part because they're confident that the IPO market will return soon.